Drug major Lupin today said its wholly-owned Japanese subsidiary, Kyowa, plans to set up a manufacturing plant at Tottori, Japan as part of expansion plans in the country.
"In order to meet the rapidly growing demand of generics, the Kyowa board has proposed the setting-up of a two billion tablets capacity plant at Tottori, Japan which would be designed to efficiently handle mass volume products and provide flexibility in allowing easy future expansion," Lupin Ltd said in a regulatory filing.
Kyowa Pharmaceutical Industry Co is a wholly-owned subsidiary of the the Mumbai-based firm. It has a manufacturing facility at Sanda, Japan.
The drug maker, however, did not disclose financial details regarding the proposed plant.
Lupin shares roday settled at Rs 1,752.15 on BSE, up 1.42 per cent from the previous close.
